SECsense Logo

XORTX Therapeutics Inc. 6-K Report: Key Financials & Updates (Dec 2024)

$XRTX
Form 6-K
Filed on: 2024-12-19
Source
XORTX Therapeutics Inc. 6-K Report: Key Financials & Updates (Dec 2024)

Here are the key insights extracted from the financial report (Form 6-K) for XORTX Therapeutics Inc.:

  1. Report Type and Date: This is a Form 6-K filing, which is typically used by foreign companies to report significant events. The reporting date is December 19, 2024.
  2. Company Details:
  • Name: XORTX Therapeutics Inc.
  • Address: 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1.
  • Commission File Number: 001-40858.
  1. Annual Reports: The registrant indicated that it files annual reports under Form 20-F, which is typically used by foreign companies to provide detailed financial information to the SEC.
  2. Signature Section:
  • The report is signed by Allen Davidoff, who holds the title of Chief Executive Officer.
  • The signing date is December 19, 2024.
  1. Press Release: The report references a press release issued on the same date, which is attached as Exhibit 99.1. This document may contain additional significant information about the company’s operations or financials on that date.
  2. Exhibit Index: The report includes an index for the attached exhibit, specifically highlighting the news release dated December 19, 2024.

These elements provide a concise overview of the filing, indicating that XORTX Therapeutics is actively reporting to the SEC, and a significant update may have been communicated through the referenced press release. Further analysis of Exhibit 99.1 would be necessary to glean additional insights about the company's current activities or financial performance.